217 related articles for article (PubMed ID: 17656558)
1. Epothilones in prostate cancer: review of clinical experience.
Dawson NA
Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
[TBL] [Abstract][Full Text] [Related]
2. Epothilones in breast cancer: review of clinical experience.
Fornier MN
Ann Oncol; 2007 Jul; 18 Suppl 5():v16-21. PubMed ID: 17656557
[TBL] [Abstract][Full Text] [Related]
3. Potential clinical applications of epothilones: a review of phase II studies.
Larkin JM; Kaye SB
Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
[TBL] [Abstract][Full Text] [Related]
4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
5. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
Lee JJ; Kelly WK
Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
[TBL] [Abstract][Full Text] [Related]
6. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
7. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Fumoleau P; Coudert B; Isambert N; Ferrant E
Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
[TBL] [Abstract][Full Text] [Related]
8. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
9. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
10. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
13. The epothilones: new therapeutic agents for castration-resistant prostate cancer.
Dorff TB; Gross ME
Oncologist; 2011; 16(10):1349-58. PubMed ID: 21964003
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
15. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Mancuso A; Oudard S; Sternberg CN
Crit Rev Oncol Hematol; 2007 Feb; 61(2):176-85. PubMed ID: 17074501
[TBL] [Abstract][Full Text] [Related]
16. Novel chemotherapies in development for management of castration-resistant prostate cancer.
Tewari AK; George DJ
Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
Andreopoulou E; Muggia F
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
[TBL] [Abstract][Full Text] [Related]
18. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
19. Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I; Oza AM
Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
